Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Zura Bio LimitedNASDAQ: ZURA
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$248.77M, compared with -$173.34M a year earlier.
Context
- Retained earnings amounted to 108.8% of total assets at the end of Q1 FY2026, up 8.3 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -43.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (224.55M) USD
- Year-over-year change
- -44.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (224.55M) | -44.0% |
| FY2024 | 2024-12-31 | (155.9M) | -50.6% |
| FY2023 | 2023-12-31 | (103.49M) | -222.9% |
| FY2022 | 2022-12-31 | (32.06M) | -249.1% |
| FY2021 | 2022-03-31 | (9.18M) | — |
Retained Earnings vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 retained earnings of -$248.77M is the 2nd highest of the 11 companies compared; the peer median is -$504M.
- Its year-over-year change of -43.5% is the 9th highest of 11, against a peer median of -16.9%.
- Retained earnings amounts to 108.8% of total assets for ZURA, versus a peer median of 257.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$137.51M | -103.3% | — | 139.5% | |
ZURAZura Bio Limited | Mar 2026 | -$248.77M | -43.5% | — | 108.8% |
| Mar 2026 | -$346.72M | -19.7% | — | 195.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$357M | -13.9% | — | 331.3% |
| Mar 2026 | -$429.96M | -16.8% | — | 136.6% | |
| Mar 2026 | -$466.45M | -21.2% | — | 725.4% | |
| Mar 2026 | -$541.55M | -17.0% | — | 220.7% | |
| Mar 2026 | -$624.28M | -15.3% | — | 462.2% | |
| Mar 2026 | -$652.34M | -13.1% | — | 293.6% | |
| Mar 2026 | -$841.13M | -0.8% | — | 357.2% | |
| Mar 2026 | -$293.78B | -122645.6% | — | 136.8% | |
| Peer median (excluding ZURA) | -$504M | -16.9% | — | 257.1% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.